Shares of digital medical services platform Teladoc Health (NYSE:TDOC) jumped 13.5% in the morning session after the company reported fourth-quarter results that surpassed analyst expectations, along with a narrower loss, even as it provided a cautious outlook for the year ahead. The virtual healthcare company posted revenue of $642.3 million, which was slightly ahead of Wall Street's estimates. A key positive for investors was the improvement on the bottom line, with the quarterly loss per share narrowing to $0.14 from $0.28 in the same period of the previous year. This result also beat market forecasts. However, the company's guidance for the upcoming first quarter and the full year 2026 came in below what analysts had anticipated. Despite the soft forecast, the market's positive reaction suggested investors placed more weight on the strong quarterly performance and improved profitability.
Digital medical services platform Teladoc Health (NYSE:TDOC) reported Q4 CY2025 results exceeding the market’s revenue expectations, but sales were flat year on year at $642.3 million. On the other hand, next quarter’s revenue guidance of $609 million was less impressive, coming in 3.8% below analysts’ estimates. Its GAAP loss of $0.14 per share was 24% above analysts’ consensus estimates.
Unprofitable companies face headwinds as they struggle to keep operating expenses under control.
Some may be investing heavily, but the majority fail to convert spending into sustainable growth.
Teladoc Health saw a serious boom during the COVID-19 pandemic, but with stagnant and declining revenue and a lack of profitability, this company looks like it might end up as a relic of a brief but bygone era.
The digital healthcare landscape faced a harsh reality check on February 6, 2026, as shares of Doximity, Inc. (NYSE: DOCS) plummeted 17% in early trading. Despite reporting fiscal third-quarter results that surpassed analyst estimates for both revenue and earnings, the professional network for physicians issued a tepid outlook for the
Wall Street has set ambitious price targets for the stocks in this article.
While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Shares of digital medical services platform Teladoc Health (NYSE:TDOC) fell 5.6% in the afternoon session after BofA Securities lowered its price target on the stock as concerns grew over expiring Medicare telehealth reimbursements.
Teladoc’s stock price has taken a beating over the past six months, shedding 26.8% of its value and falling to $6.10 per share. This might have investors contemplating their next move.
Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts.
But that doesn’t mean the underlying businesses are cheap, and we advise caution as many have questionable fundamentals.
The digital health landscape faced a sobering milestone this week as shares of Doximity, Inc. (NYSE: DOCS), the leading professional network for physicians, plummeted to a new 52-week low. On January 12, 2026, the stock touched $43.21, marking a dramatic retreat from its February 2025 peak of $85.21.
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer.
However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
As of January 1, 2026, the landscape of digital health in California has undergone a seismic shift with the full implementation of Assembly Bill 489 (AB 489). Known colloquially as the "No AI Doctor" law, this landmark legislation marks the most aggressive effort yet to regulate how artificial intelligence presents itself to patients. By prohibiting [...]
A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south.
While some investors embrace risk, mistakes can be costly for those who aren’t prepared.
A number of stocks fell in the afternoon session after heavyweight stocks retreated, pulling back from recent record highs as the year-end rally showed signs of fatigue.
Shares of digital medical services platform Teladoc Health (NYSE:TDOC) jumped 2.8% in the morning session after Barclays initiated coverage on the company with an Equal Weight rating and an $8.50 price target.
